As for the study group, which included laryngeal cancer patients and their division into EBV+ and EBV- patients, statistical significance was observed only in the case of CD19+CD69+ B-lymphocytes in the blood, as well as CD4+PD-1. This evidence concerns the gene CD19 and laryngeal carcinoma.